| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 07/10/2001 | US6258817 Substituted pyrazin-2-yl-sulphonamide (-3-pyridyl) compounds and uses thereof |
| 07/10/2001 | US6258815 Specific immunophilin ligands as antiasthmatics and immunosuppressants |
| 07/10/2001 | US6258813 D4 receptor selectivity piperazine derivatives |
| 07/10/2001 | US6258812 Phthalazines with angiogenesis inhibiting activity |
| 07/10/2001 | US6258811 Methods for preventing, inhibiting or treating graft rejection reactions in graft-versus-host disease (GVHD) and organ transplantation |
| 07/10/2001 | US6258804 Triazepinones, process for their preparation and their therapeutic application |
| 07/10/2001 | US6258802 Corticoid therapy |
| 07/10/2001 | US6258800 Prodrugs of benzofuranylethyl carbamate NK1 antagonists |
| 07/10/2001 | US6258790 Antisense modulation of integrin α4 expression |
| 07/10/2001 | US6258782 Hybrid polypeptides with enhanced pharmacokinetic properties |
| 07/10/2001 | US6258780 Method and composition for enabling passage through the blood-brain-barrier |
| 07/10/2001 | US6258778 Methods for accelerating bone and cartilage growth and repair |
| 07/10/2001 | US6258774 Carrier for in vivo delivery of a therapeutic agent |
| 07/10/2001 | US6258600 Antisense modulation of caspase 8 expression |
| 07/10/2001 | US6258584 Drug screening for modulators of collagen formation by measuring enzyme activity in presence and absence of compound; reduced activity indicates enzyme inhibitor; antiarthritic agents; antiscarring agents |
| 07/10/2001 | US6258580 Amino acid sequence of adaptor protein required for g protein-dependent activation of phosphatidylinositol-3-kinase; drug screening; diagnosis; antiarthritic agents; antiinflammatory agents; adult respiratory distress syndrome |
| 07/10/2001 | US6258579 I-kappa-b kinase signalsome capable of specifically phosphorylating i-kappa-b-alpha and i-kappa-b-beta; antiinflammatory agents; anticarcinogenic agents; viricides; treatment of autoimmune and nervous system disorders |
| 07/10/2001 | US6258578 His5 |
| 07/10/2001 | US6258557 Nucleotide sequences associated with preferential gene expression; for the treatment of vascular injury; for reducing or preventing the development of arteriosclerosis |
| 07/10/2001 | US6258364 Isolated carbohydrate epitope; immunocontraceptive vaccines; semen detection; medical diagnosis; antifertility agents |
| 07/10/2001 | US6258357 Extracting allogeneic human donor blood aliquot; separating t-cells; oxidatingstressing to reduce cytokines; administering to patient undergoing bone marrow transplant |
| 07/10/2001 | CA2175643C Utilization of retinoids in a cosmetic composition or in the preparation of a pharmaceutical composition |
| 07/10/2001 | CA2175502C Cyclic amide derivatives |
| 07/10/2001 | CA2059792C Tricyclic compounds and intermediates thereof |
| 07/10/2001 | CA2017135C Substituted (quinolin-2-yl-methoxy)phenyl-acyl-sulphonamides and -cyanamides, processes for their preparation and their use in medicaments |
| 07/05/2001 | WO2001048238A2 Chemotherapeutant screening method |
| 07/05/2001 | WO2001048233A1 Viral core protein-cationic lipid-nucleic acid-delivery complexes |
| 07/05/2001 | WO2001048231A2 Method of achieving persistent transgene expression |
| 07/05/2001 | WO2001048209A2 Genes identified as required for proliferation of e. coli |
| 07/05/2001 | WO2001048203A1 Novel protein and dna thereof |
| 07/05/2001 | WO2001048188A1 Novel guanosine triphosphate-binding protein-coupled receptors, genes thereof and production and use of the same |
| 07/05/2001 | WO2001048171A1 IDENTIFICATION OF NOVEL SPLICE VARIANTS OF THE HUMAN CATALYTIC SUBUNIT Cβ OF cAMP-DEPENDENT PROTEIN KINASE AND THE USE THEREOF |
| 07/05/2001 | WO2001048154A1 Maturation-promoting agent for immature dendritic cells |
| 07/05/2001 | WO2001047950A2 Basolateral sorting signal based on scf peptide and inhibitors thereof |
| 07/05/2001 | WO2001047946A2 GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 07/05/2001 | WO2001047943A1 Antisense modulation of akt-3 expression |
| 07/05/2001 | WO2001047935A2 Novel bisamidate phosphonate prodrugs |
| 07/05/2001 | WO2001047930A1 Carboxamide diazepin derivatives, preparation method, use as medicines, pharmaceutical compositions and use thereof |
| 07/05/2001 | WO2001047929A1 Triazolotriazinones and the use thereof |
| 07/05/2001 | WO2001047928A2 Imidazo 1,3,5 triazinones and the use thereof |
| 07/05/2001 | WO2001047927A1 Compound and method for the treatment of pain |
| 07/05/2001 | WO2001047922A2 Azaindoles |
| 07/05/2001 | WO2001047921A1 Pyrimidine and triazine kinase inhibitors |
| 07/05/2001 | WO2001047919A1 Substituted oxazolidinones and their use in the field of blood coagulation |
| 07/05/2001 | WO2001047914A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047905A1 Pyrrolidine derivatives as cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047901A1 Ox(adi)azolyl-hydroxamic acids useful as procollagen c-proteinase inhibitors |
| 07/05/2001 | WO2001047897A1 Cytokine, especially tnf-alpha, inhibitors |
| 07/05/2001 | WO2001047896A1 Benzimidazoles, production thereof and the use thereof as antithrombotic |
| 07/05/2001 | WO2001047892A1 Tricyclic protein kinase inhibitors |
| 07/05/2001 | WO2001047891A1 Heterocyclic compounds having sulfonamide groups |
| 07/05/2001 | WO2001047890A1 Quinoline and quinazoline derivatives and drugs containing the same |
| 07/05/2001 | WO2001047889A1 Tricyclic compounds |
| 07/05/2001 | WO2001047887A1 β-AMINO ACID COMPOUNDS AS INTEGRIN ANTAGONISTS |
| 07/05/2001 | WO2001047885A1 Substituted indole mannich bases |
| 07/05/2001 | WO2001047880A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 07/05/2001 | WO2001047879A1 Pyrrolidines which inhibit camp-specific pde |
| 07/05/2001 | WO2001047875A1 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone |
| 07/05/2001 | WO2001047874A1 (hetero)bicyclymethanesulfonylamino-substituted hydroxamic acid derivatives |
| 07/05/2001 | WO2001047859A1 Compounds active at the glucocorticoid receptor |
| 07/05/2001 | WO2001047563A1 Use of lithium (li+) for the preparation of a composition for transfection of a polynucleotide into a cell and compositions useful in gene therapy |
| 07/05/2001 | WO2001047562A2 Hydrolytically degradable carbamate derivatives of poly(ethylene glycol) |
| 07/05/2001 | WO2001047561A1 Hyaluronic acid in the treatment of cancer |
| 07/05/2001 | WO2001047556A1 Composition promoting lacrimal secretion |
| 07/05/2001 | WO2001047541A1 Optimized minigenes and peptides encoded thereby |
| 07/05/2001 | WO2001047537A1 Method for obtaining olive leaf extracts and applications thereof |
| 07/05/2001 | WO2001047533A2 INHIBITION OF GSK-3$g(b) |
| 07/05/2001 | WO2001047528A2 Novel glycosidase inhibitors and their pharmacological uses, in particular for treating diabetes |
| 07/05/2001 | WO2001047524A1 Method and composition for the treatment of pain |
| 07/05/2001 | WO2001047510A2 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 07/05/2001 | WO2001047508A2 Combination of trimebutine with an opioid analgesic |
| 07/05/2001 | WO2001047507A2 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound |
| 07/05/2001 | WO2001047499A1 Pharmaceutical formulations comprising sodium amoxycillin and potassium clavulanate |
| 07/05/2001 | WO2001047498A2 Hydrogel-driven layered drug dosage form comprising sertraline |
| 07/05/2001 | WO2001047492A1 Improved pharmaceutical compositions for poorly soluble drugs |
| 07/05/2001 | WO2001012592A3 Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors |
| 07/05/2001 | WO2001003720A9 Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs |
| 07/05/2001 | WO2001000824A3 HUMAN PROTEINS HAVING HYDROPHOBIC DOMAINS AND DNAs ENCODING THESE PROTEINS |
| 07/05/2001 | WO2001000822A3 Cdna sequences of two interacting fancip2 and fancip3 of the fanconi anemia complementation group a protein |
| 07/05/2001 | WO2000076552A8 Methods and compositions for control of bone formation via modulation of leptin activity |
| 07/05/2001 | WO2000073278A3 5-phenyl-pyrimidine derivatives |
| 07/05/2001 | WO2000071679A3 Human oxidoreductase proteins |
| 07/05/2001 | WO2000069896A3 Molecular interactions in haematopoietic cells |
| 07/05/2001 | WO2000068195A3 Substituted pyrrolidines as cell adhesion inhibitors |
| 07/05/2001 | WO2000055137A8 Compounds and methods for modulation of estrogen receptors |
| 07/05/2001 | WO2000052134A3 Inhibitors of prenyl-protein transferase |
| 07/05/2001 | WO2000040247A8 2-oxy-benzoxazinone derivatives for the treatment of obesity |
| 07/05/2001 | WO2000023114A9 Polymer conjugates of interferon beta- 1a and their uses |
| 07/05/2001 | WO1999064045A9 Novel therapeutic agents for membrane transporters |
| 07/05/2001 | WO1999053910A8 Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 07/05/2001 | US20010007152 Obtained by immunizing transgenic mice which produce human leukocyte antigen (HLA) with tumor-associated antigens and recovering the nucleic acids encoding the T cell receptors from the cytotoxic T lymphocytes; diagnosis and therapy |
| 07/05/2001 | US20010007025 Antisense modulation of bcl-x expression |
| 07/05/2001 | US20010007019 Useful in methods for the induction of bone, cartilage and tissue formation, growth and development of the endometrium and in the acceleration of wound healing |
| 07/05/2001 | US20010007015 Can be used as the basic structures (template molecules) for inhibiting and analysing amyloid formation and cytotoxicity in amyloid illnesses |
| 07/05/2001 | US20010006973 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels |
| 07/05/2001 | US20010006967 Administering an analgesic amount of tramadol and an amount of an excitatory opioid receptor antagonist, e.g naltrexone, nalone, to lessen the antianalgesia, hyperalgesia, hyper-excitability, physical dependence and or tolerance |
| 07/05/2001 | US20010006947 Methods of administering adenoviral vectors |
| 07/05/2001 | US20010006939 Secretory leukocyte protease inhibitor dry powder pharmaceutical compositions |
| 07/05/2001 | US20010006686 Extract; antiinflammatory agent for treatment of cyclooxygenase-2 (COX-2) conditions such as arthritis, pain from cancer; selective inhibition of COX-2 over COX-1 |
| 07/05/2001 | US20010006642 Delivering antigens or biologically active polypeptides to a subject in need of same by administering to the subject a non-invasive or non-pathogenic bacterium which expresses the antigens or polypeptides |